Throcare Technologies Ltd (BSE: 539871) is a Navi Mumbai, Maharashtra-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹7,764 Cr, it ranks #671 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 18 in Medical Diagnostic Centres. At ₹497.95 (as of 16 Nov 2026), the share price is 24.8% below its 52-week high of ₹662.00 and 45.4% above its 52-week low of ₹342.55. The share price is up 7.5% over one year and down 17.8% over three months.
| Current Price | ₹497.95 |
|---|---|
| Market Cap | ₹7,764 Cr |
| BSE Code | 539871 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 47.6 |
| Return on Equity | 28.74% |
| Return on Assets | 17.69% |
| 52-Week Range | ₹342.55 – ₹662.00 |
| 1-Year Price Change | +7.5% |
| 3-Month Price Change | -17.8% |
| Beta (1Y) | 0.84 |
| Dividend Yield | 2.88% |
| Headquarters | Navi Mumbai, Maharashtra |
| Website | www.thyrocare.com |
| Revenue | ₹271 Cr |
|---|---|
| Net Profit | ₹15 Cr |
| Net Margin | 5.6% |
| EPS (Basic) | ₹0.96 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Throcare Technologies Ltd reported revenue of ₹271 Cr in Q2 FY27, up 25.1% from ₹217 Cr in Q2 FY26 and up 12.8% from ₹240 Cr in Q1 FY27. It posted a net profit of ₹15 Cr for the quarter, against a net profit of ₹48 Cr in Q2 FY26 (down 68.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹187 Cr (Q4 FY25) to ₹271 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹271 Cr | ₹15 Cr | 5.6% |
| Q1 FY27 | ₹240 Cr | ₹51 Cr | 21.4% |
| Q4 FY26 | ₹224 Cr | ₹49 Cr | 21.7% |
| Q3 FY26 | ₹196 Cr | ₹28 Cr | 14.3% |
| Q2 FY26 | ₹217 Cr | ₹48 Cr | 22.1% |
| Q1 FY26 | ₹193 Cr | ₹38 Cr | 19.8% |
| Q4 FY25 | ₹187 Cr | ₹22 Cr | 11.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 51.02% of Throcare Technologies Ltd's shares as of Sept 2026, against 71.06% in Sept 2025 (−20.04 percentage points). Delivery averaged 49.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment engages in the selling of consumables used for collection, and promotion of pathology. The Imaging Services segment sells radio-pharmaceutical and consumables for reporting. The Others segment engages in the sale of testing equipment and consumables; and glucometer and glucostrips under the brand name sugarscan. The company offers diagnostic and pathological services. The company was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
1. Diagnostic Testing Services-This segment provides laboratory testing services. 2. Imaging Services-This segment provides PET-CT scanning services; and sells radio pharmaceuticals used in imaging services. 3. Others-This segment engages in trading and other related business activities. 4. Unallocable Assets-0
1. Diagnostic Testing Services-93.2% 2. Imaging Services-6.4% 3. Others-0.4%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs Ltd | ₹33,934 Cr | 66.4 | 21.48% | ₹874 Cr | +28.7% |
| Vijaya Diagnostic Centre Limited | ₹14,665 Cr | 84.3 | 19.70% | ₹255 Cr | +38.5% |
| Metropolis Healthcare Limited | ₹11,952 Cr | 61.5 | 13.37% | ₹497 Cr | +14.9% |
| Throcare Technologies Ltd | ₹7,764 Cr | 47.6 | 28.74% | ₹271 Cr | +7.5% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,856 Cr | 55.4 | 13.84% | ₹99 Cr | +6.9% |
| Krsnaa Diagnostics Ltd | ₹1,625 Cr | 16.8 | 10.89% | ₹271 Cr | -27.0% |
| Gaudium IVF and Women Health Limited | ₹803 Cr | 27.4 | 16.08% | ₹37 Cr | — |
| Chandan Healthcare Limited | ₹582 Cr | 21.9 | 18.43% | ₹81 Cr | — |
| Aspira Pathlab & Diagnostics Ltd | ₹127 Cr | 2,360 | — | — | +115.2% |
Listed by market capitalisation. Ratios are shown for context only.
Throcare Technologies Ltd is trading at ₹497.95, with a market capitalisation of ₹7,764 Cr.
Throcare Technologies Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Throcare Technologies Ltd has a P/E of 47.6 and a return on equity of 28.74%.
Throcare Technologies Ltd is listed on the BSE under the scrip code 539871.
Throcare Technologies Ltd's share price is up 7.5% over one year and down 17.8% over three months. Its 52-week range is ₹342.55 to ₹662.00.
In Q2 FY27, Throcare Technologies Ltd reported revenue of ₹271 Cr and net profit of ₹15 Cr, with basic EPS of ₹0.96 (consolidated, parsed from the company's exchange filing).
Throcare Technologies Ltd reported revenue of ₹271 Cr in Q2 FY27, up 25.1% from ₹217 Cr in Q2 FY26 and up 12.8% from ₹240 Cr in Q1 FY27.
Promoters held 51.02% of Throcare Technologies Ltd's shares as of Sept 2026, against 71.06% in Sept 2025 (−20.04 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.